<DOC>
	<DOCNO>NCT01583881</DOCNO>
	<brief_summary>Increasing evidence suggest important role activation sympathetic nervous system ( SNS ) clinical phenomenon heart failure normal leave ventricular ejection fraction hypertension . The current study aim evaluate efficacy safety renal sympathetic denervation modulation SNS patient heart failure normal LV ejection fraction .</brief_summary>
	<brief_title>Denervation renAl sympathetIc nerveS hearT Failure With nOrmal Lv Ejection Fraction</brief_title>
	<detailed_description>Rationale : Increasing evidence suggest important role activation sympathetic nervous system ( SNS ) clinical phenomenon heart failure normal leave ventricular ejection fraction hypertension . Moreover , sympathetic activation kidney directly proportional related severity heart failure state . Therapeutic renal denervation ( PRDN ) , deliberate disruption nerve connect kidneys central nervous system , show effective mean modulate elevated SNS activity . The current study aim evaluate efficacy safety renal sympathetic denervation modulation SNS patient heart failure normal LV ejection fraction . Objective : Primary objective : To investigate efficacy PRDN mean pulse wave Doppler echocardiographic parameter patient diagnose HFNEF hypertension . Secondary objective : investigate safety PRDN patient heart failure normal LV ejection fraction hypertension compare change follow parameter patient HFNEF hypertension PRDN : LV mass , LV volume , LA volume , LVEF , MIBG-uptake -washout , BNP level , blood pressure , heart rate variability , exercise capacity quality life . Study design : Multicentre , prospective , randomise control trial . 60 patient randomly allocate one-to-one ratio undergo renal denervation previous treatment ( n=30 ) maintain previous treatment alone ( n=30 ) 2 participate centre . Randomisation do seal envelope . Study population : Patients diagnose heart failure normal LV ejection fraction treat hypertension . Patients stable drug regimen , least 2 antihypertensive agent . This drug regimen expect maintain least 6 month . ￼￼￼￼￼￼￼￼￼Endpoints : The efficacy PRDN evaluate primarily use echocardiographic parameter . Also , safety PRDN major minor adverse event , LV mass , LV LA dimension , MIBG uptake clinical endpoint evaluate .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<criteria>Individual diagnose heart failure normal LV ejection fraction . The diagnosis HFNEF require follow condition satisfy : sign symptom heart failure ; normal mildly abnormal systolic LV function ( LVEF ≥ 50 % ) ; evidence diastolic LV dysfunction . Individual fulfill diagnostic WHO criterion hypertension : SBP &gt; 140 mmHg and/or DBP &gt; 90 mmHg , treat least 2 antihypertensive drug . This treatment expect maintain least 6 month . Using regimen blood pressure adequately control ( &lt; 140/90mmHg 24 hour ambulatory BP measurement ) . Individual adhere stable drug regimen HFNEF , change minimum 2 week prior enrollment , expect maintain least 6 month . Individual ≥ 18 year age . Known secondary cause hypertension Anatomy eligible renal denervation Systolic heart failure ( LVEF &lt; 50 % ) Individual estimate glomerular filtration rate ( eGFR ) &lt; 30mL/min/1.73m2 , use MDRD calculation . Individual serious medical condition , opinion investigator , may adversely affect safety and/or effectiveness participant study ( i.e. , patient clinically significant peripheral vascular disease , abdominal aortic aneurysm , bleed disorder thrombocytopenia , haemophilia , significant anaemia , arrhythmias atrial fibrillation ) . Individual pregnant , nurse planning pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Patients diastolic heart failure hypertension</keyword>
</DOC>